Summary
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
History
Nabriva Therapeutics was established in 2005 and is headquartered in Vienna, Austria. The company is developing anti-infectives to treat serious infections. Nabriva was the first company to receive U.S. Food and Drug Administration (FDA) approval for lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).
Mission
At Nabriva Therapeutics, we seek to help those with serious infections get better by developing and commercializing novel anti-infective agents.
Vision
We aspire to be the global leader in delivering novel therapeutics to the fight against serious infections.
Key Team
Mr. Daniel Dolan (Chief Financial Officer)
Mr. J. Christopher Naftzger BA, Esq., J.D. (Gen. Counsel & Sec.)
Ms. Jodi VanDerveer (Sr. VP & Head of HR)
Dr. Christine J. Guico-Pabia M.B.A., M.D., M.P.H. (Chief Medical Officer)
Mr. Gary L. Sender (Consultant)
Mr. Werner Heilmayer (VP of CMC & IP)
Recognition and Awards
Nabriva Therapeutics has won several prestigious awards, including the Sanofi Innovation Award, the National Institute of Allergy and Infectious Diseases Director's Award, the NESTA PRIZE for Innovation in Health, and several U.S. patents for its anti-infective agents.
References
Ireland 